ADMA Biologics Faces Class Action Lawsuit

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 1 hour ago

0mins

ADMA-1.95%

Explore Agentic TradingLet AI Trade for You

Source: Globenewswire

Lawsuit Background: Gainey McKenna & Egleston has filed a securities class action lawsuit in the U.S. District Court for New Jersey on behalf of all ADMA Biologics investors who purchased shares between August 9, 2024, and March 25, 2026, alleging undisclosed related party transactions and inadequate internal controls.
Allegation Details: The complaint claims that ADMA engaged in channel stuffing to inflate revenue figures and failed to disclose related party transactions, resulting in materially misleading statements about the company's business and prospects, which could mislead investors.
Stock Price Reaction: Following a report from Culper Research on March 24, 2026, ADMA's stock price fell by $2.26, or 16.6%, and dropped another $1.70 the next day, indicating increasing market concerns regarding the company's financial health and operational integrity.
Investor Action: Affected investors are urged to contact the law firm before the August 10, 2026, lead plaintiff motion deadline to ensure their rights are represented in the class action lawsuit.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ADMA

About ADMA

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ADMA Biologics Class Action Lawsuit Notice

13 minutes agoPRnewswire

Class Action Initiation: ADMA Biologics faces a class action lawsuit for alleged violations of the Securities Exchange Act during the period from August 9, 2024, to March 25, 2026, with investors required to apply as lead plaintiffs by August 10, 2026, highlighting the urgency of the legal risks facing the company.
False Statement Allegations: The lawsuit accuses ADMA Biologics of failing to disclose related party transactions and using channel stuffing to inflate revenues, resulting in significant investor losses and indicating severe deficiencies in the company's internal controls.
Stock Price Volatility: Following a report from Culper Research, ADMA Biologics' stock price fell over 16% on March 24, 2026, and dropped more than 13% again on March 26 after Cantor Fitzgerald downgraded its rating, reflecting market concerns about the company's financial health.
Lead Plaintiff Selection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased ADMA securities during the class period can seek to be appointed as lead plaintiff, emphasizing the importance of investor participation in legal actions and its potential impact on the company's future recovery.